WESTBOROUGH, MA -- (MARKET WIRE) -- 03/13/2006 -- More than 300 executives and scientists from the biopharmaceutical industry will meet on June 13-15 to discuss pharmaceutical and biotech R&D and business partnerships in China. The conference China BioPharma Opportunities will take place at the Riverfront Business Hotel, Shanghai. 80 speakers from around the globe will discuss how companies can reduce R&D costs, enrich the pipeline and extend market reach.

The event will include the following keynote presentations:

--  Progress of Biomedicine and Biotechnology in China
    Zhu Chen, M.D., Ph.D., Vice President, Chinese Academy of Science
    
--  Expanding the Innovation Model: Investing R&D in China
    Lee Babiss, Ph.D., Vice President, Pre-Clinical R&D Hoffmann-La Roche
    
--  Changing the Partnership Paradigm: The Wyeth Approach
    Frank Walsh, Ph.D., Senior Vice President, Discovery Wyeth Research
    

The conference and exhibition will address scientific advances of medical sciences industry in China, clinical trials challenges and opportunities, pre-clinical development, IP and regulatory issues, and R&D and corporate development.

The event includes case studies on partnering strategies for East-West alliances from AstraZeneca (China), Pfizer Global Research & Development (USA), Synergenics (USA), TageGen (USA), Shanghai Genomics (China), GNI Limited (Japan), Aura Partners (China), Debiopharm (France), and Eli Lilly and Company (USA).

Panel discussions on valuation and investment interests in China's biotechs, and expectations, experiences, results, and the future of global partnerships will be conducted by experts from USA, China, Denmark, Australia, Singapore, Canada and Japan.

This event is supported by the local Chinese government. For more information about China BioPharma Opportunities visit http://www.drugdisc.com/China.